NK-Cell-Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy-Induced Senescent steosarcoma Cells
Quick Facts
- Publication title: NK-Cell-Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy-Induced Senescent steosarcoma Cells
- Journal: J Extracell Vesicles
- Year: 2025
- DOI: 10.1002/jev2.70123
- PMID/PMCID: 40693561; PMC12281467
Research overview
In order to further improve the efficacy of chemotherapy on OS, here we developed a senolytic drug delivery system based on engineered Natural killer (NK) cell-derived extracellular vesicles (EVs) that can target OS cells. Treatment-induced senescence (TIS) can lead to incomplete tumour clearance and potential recurrence.
Key findings
Osteosarcoma (OS) is a type of bone tumour characterized by high risk of metastatic progression and recurrence after therapy.
Traditional tumour treatment methods such as radiotherapy and chemotherapy can lead to the accumulation of senescent cells in tumours.
Treatment-induced senescence (TIS) can lead to incomplete tumour clearance and potential recurrence.
Recently, the combination of chemotherapy drugs and senolytics drugs ('one-two punch' therapy) has become a promising strategy for improved tumour treatment, but this method also faces challenges in terms of safety and targeting specificity.
Echo Biotech Role
Echo Biotech contributed targeting-peptide/surface modification; the study also used or cited ExoBrooch™.
Related platforms: Echosome®, Research Reagents & Tools
Related services and capabilities: Targeting Peptide / Surface Modification, Research Reagent / Product Supply
Related products or reagents: ExoBrooch™ Targeting Peptide/Lipid Anchor Kit
References
Original publication: NK-Cell-Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy-Induced Senescent steosarcoma Cells Journal of Extracellular Vesicles. 2025. DOI: 10.1002/jev2.70123. PMID/PMCID: 40693561; PMC12281467.